{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.96","upperLimit":"5.12","value":"4.50"},{"groupId":"OG001","lowerLimit":"6.22","upperLimit":"8.07","value":"7.08"}]}],"title":"hsCRP : Core(n= 109, 107)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.57","upperLimit":"8.21","value":"6.77"},{"groupId":"OG001","lowerLimit":"14.01","upperLimit":"20.62","value":"17.00"}]}],"title":"SAA protein : Core (n=105, 106)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.79","upperLimit":"7.09","value":"5.18"},{"groupId":"OG001","lowerLimit":"5.27","upperLimit":"9.77","value":"7.18"}]}],"title":"hsCRP : 24 weeks(n= 31, 32)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.76","upperLimit":"16.84","value":"11.43"},{"groupId":"OG001","lowerLimit":"14.78","upperLimit":"30.16","value":"21.11"}]}],"title":"SAA protein : 24 weeks (n=28, 33)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"High sensitivity C-reactive protein (hsCRP) and serum amyloid A (SAA) were determined in blood serum in order to identify the presence of inflammation, to determine its severity, and to monitor the response to treatment. Analytes were measured by a central laboratory. The analysis included treatment group, log-transformed protein level at baseline, and body mass index (BMI) at baseline as covariates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.","id":"OG000","title":"Canakinumab 150 mg"},{"description":"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.","id":"OG001","title":"Triamcinolone Acetonide 40 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set (FAS) consisted of all patients as randomized in core study who had taken at least one dose of study drug. Patients with baseline flare and data at 72 hours post-dose in core and patients with a new flare and data at 72 hours post-dose for the last post-baseline flare (during 24 weeks overall) were included in this analysis.","reportingStatus":"POSTED","timeFrame":"72 hours post-dose (randomization), 72 hours post-dose for the last post-baseline flare (during 24 weeks overall)","title":"High-sensitivity C-reactive Protein (hsCRP) and Serum Amyloid A Protein (SAA) Levels for Core and 24 Weeks Overall","type":"SECONDARY","unitOfMeasure":"mg/L"}